ClinicalTrials.gg
RecruitingNCT04808596PHBRUpdated Aug 1, 2025

Pulmonary Hypertension Biorepository and Registry

An observational study in Pulmonary Hypertension, Pulmonary Arterial Hypertension and Pulmonary Hypertension Due to Left Heart Disease, sponsored by University of Kansas Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-01.

Primary conditionPulmonary Arterial HypertensionRegistry: Hypertension, PulmonaryReclassifiedWhy we changed it
Registry
Hypertension, Pulmonary — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Arterial Hypertension
Why
  1. The study's listed conditions name Pulmonary Arterial Hypertension, a narrower term within Hypertension, Pulmonary.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Kansas Medical Center · Observational

How we know

From the registry’s dates

  • Started Aug 2020; still recruiting 6 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 313 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Planned enrollment
21st of 60
300 · median 59
Started
2020
with 8 others
Observational
60 of 313
10 open now
Primary completion
2026-12
later than 14 of 55 live
Registered
242nd of 313
by date

Among the 313 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 21st largest by planned enrollment of the 60 observational ones that give a count, is one of 9 that started in 2020, is one of 60 observational ones, reaches primary completion later than 14 of the 55 other live ones, and was the 242nd registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

38 of the 313 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.

Read the detailed description

The aim of this project will be to establish a broad and wide-ranging registry and biorepository of blood samples from patients with pulmonary hypertension, including all WHO groups I-V to be used for future research in these areas. This will be both a retrospective and prospective project. The registry and biorepository will be utilized to study and grow our knowledge of the cellular mechanisms and mediators of the disease and, in turn, contribute to advancements in treatment.

03

Conditions studied

  • Pulmonary Hypertension
  • Pulmonary Arterial Hypertension
  • Pulmonary Hypertension Due to Left Heart Disease
  • Pulmonary Hypertension, Primary
  • Pulmonary Hypertension Due to Lung Diseases and Hypoxia
  • Pulmonary Hypertension, Primary, 4
  • Pulmonary Hypertension, Primary, 2
  • Pulmonary Hypertension, Primary, 3
  • Chronic Thromboembolic Pulmonary Hypertension

Browse trials for

04

In context

Pulmonary Arterial Hypertension Reclassified

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

This study's planned enrollment of 300 is above the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

University of Kansas Medical Center is the lead sponsor of 493 studies on the registry; 111 are open to participants now.

Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.

Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Pulmonary Hypertension Group 1-5

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)
  2. The participant has a diagnosis of pulmonary hypertension confirmed by right heart catheterization
  3. Patient is ≥ 18 years of age or older

Exclusion criteria

Exclusion Criteria:

  1. Participant declines to participate (living patients only)
  2. Participant is unable to provide (living patients only)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
Biospecimen retention
Samples with dna
07

What researchers measure

Primary outcomes

  1. Collect Clinical Data

    Collect clinically obtained data from current and deceased patients with pulmonary hypertension to support research.

    Time frame: From Enrollment to 6 Months

  2. Establish a Biorepository

    Establish a collection of biospecimens from patients with pulmonary hypertension.

    Time frame: From Enrollment to 6 Months

  3. Biospecimens Collection

    Correlate biospecimens to longitudinally collected individual patient data.

    Time frame: From Enrollment to 12 Months

  4. Collaborate

    Provide biospecimens to researchers investigating pulmonary hypertension. Separate IRB approval will be needed for these studies.

    Time frame: From Enrollment to 24 Months

08

Study locations

1 of 1 sites recruiting
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Recruiting
    • Luigi R Boccardi, Ed.D., MPH · Contactlboccardi@kumc.edu · 9135884022
    • Kimberly Cygan, MBA, BSN, RN · Contactkcygan@kumc.edu
    • Leslie A Spikes, MD · Principal investigator
    • Lewis G Satterwhite, MD · Sub investigator
    • Timothy L Williamson, MD, FCCP · Sub investigator
09

References and documents

Individual participant data

Plan to share: Yes — Contact Luigi Boccardi to discuss accessing IPD.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Dec 2026, 76 months after the start.

Of 64 non-industry observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 31. This study's planned 76 months is above that.

Counting every sponsor, half of 85 studies reached it within 58 months; a quarter within 30 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2021
First posted
Mar 22, 2021
StartActual
Aug 10, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jul 31, 2027
Last update
Aug 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04808596
Responsible party
Leslie Spikes, MD (Associate Professor, University of Kansas Medical Center) — Principal investigator
First posted
Mar 22, 2021
Start date
Aug 10, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Aug 1, 2025

Study contacts

Luigi R Boccardi, Ed.D., MPH
Contact
lboccardi@kumc.edu
9135884022
Kimberly Cygan, MBA, BSN, RN
Contact
kcygan@kumc.edu
Leslie A Spikes, MD
principal investigator · Assistant Professor of Medicine
Luigi R Boccardi, Ed.D., MPH
study director · Director of Pulmonary Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion